Zarnie Lwin, Mbbs, Fracp, Speculates On Future Development Of Combo Pembrolizumab + Lenvatinib

Zarnie Lwin, MBBS, FRACP, speculates on future development of combo pembrolizumab + lenvatinib

Zarnie Lwin, MBBS, FRACP, on the safety and efficacy of combining TKIs with checkpoint inhibitors

Zarnie Lwin, MBBS, FRACP, shares the design & outcomes of the LEAP-005 Phase II study from ESMO 2020

Dr. Lwin on the Results of the LEAP-005 Trial in Advanced Solid Tumors

Dr. Zamarin on the Role of Pembrolizumab in Endometrial Cancer

Viktor Grünwald on CLEAR Study: Lenvatinib and Pembrolizumab for Kidney Cancer | OncoDaily

Modest Response Rates in Endometrial Cancers

Targeted Oncology

Combination Therapies Emerge in the Frontline for Renal Cell Carcinoma

Targeted Oncology

Dr. Makker on Synergy Between Lenvatinib and Pembrolizumab in Endometrial Cancer

Insights into the real-world efficacy of luspatercept in patients with LR-MDS

VJHemOnc – Video Journal of Hematology & HemOnc

The Role of Lenvatinib in NSCLC Treatment

Targeted Oncology

Discussing the Phase II Study of Lenvatinib/Pembrolizumab in Metastatic ccRCC

Targeted Oncology

The nutritional requirements of patients undergoing chemotherapy

Dr. Makker on Unmet Needs for Patients with Advanced Endometrial Cancer

The importance of biological understanding for disease management

Evaluating Systemic Therapies Available for Frontline Treatment of HCC

Targeted Oncology

Next-Generation Sequencing in Intimal Sarcoma

Targeted Oncology

Professor Lining Arnold Ju’s research

The University of Sydney

Nobel Medicine laureate Alter receives diploma

Innovation means hope: SYNAPODIA - improving immunotherapy